4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Cirrhosis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 844 ongoing clinical trials involving Cirrhosis
Of the 844 trials,338 trials are in Phase II
Furthermore, 216 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Cirrhosis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Cirrhosis, a Gastrointestinal indication. The highest number of ongoing clinical trials involving Cirrhosis is conducted in Asia-Pacific. North America and Europe are among some of the other prominent regions involved in Cirrhosis-related drug trials.

Institute of Liver and Biliary Sciences: The leading ongoing Cirrhosis-related clinical trials sponsor

Institute of Liver and Biliary Sciences, the India-based government institute, is the top sponsor for Cirrhosis-related ongoing clinical trials.

Postgraduate Institute of Medical Education and Research, National Cancer Institute US, Bristol-Myers Squibb Co, Intercept Pharmaceuticals Inc, and West China Hospital are a few other notable sponsors involving Cirrhosis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Cirrhosis

Human albumin (AlbuRx, Albuminar, Albunate, Beribumin, Albumeon, Alburex, Albumex, Albumina Umana, Alburex AU), Methylprednisolone (Solu-Medrol, Depo-Medrol, Medrol, Medrate, Depo-Medrate, Medrol Acetate, Solu-Medrone, Solu-Moderin, Depo-Medrone, Methylprednisolone Sodium Succinate, Promedrol, Medrol A, Medroxyprogesterone Acetate Greenstone), and Obeticholic acid (Ocaliva) are among the key marketed drugs involving Cirrhosis.

Human albumin (AlbuRx, Albuminar, Albunate, Beribumin, Albumeon, Alburex, Albumex, Albumina Umana, Alburex AU) is obtained by fractionation of blood plasma. It functions via the Serum Albumin (ALB) Replacement mechanism of action. It is a formulated as sterile aqueous solution for intravenous route of administration. 5 % of Human albumin solution is indicated for the treatment of shock, burns, pancreatitis and peritonitis, postoperative albumin loss and hypoproteinemia with an oncotic deficit. Its 25 % solution is indicated for albumin volume deficit, oncotic deficit, shock, burns, adult respiratory distress syndrome, cardiopulmonary bypass, pre- and postoperative hypoproteinemia, third space problems of infectious origin (peritonitis, pancreatitis, mediastinitis or extensive cellulitis). Human albumin was first approved in 1971 and is marketed globally including the US, the UK, France, Germany, China, and Japan by CSL Behring LLC.

Methylprednisolone (Solu-Medrol, Depo-Medrol, Medrol, Medrate, Depo-Medrate, Medrol Acetate, Solu-Medrone, Solu-Moderin, Depo-Medrone, Methylprednisolone Sodium Succinate, Promedrol, Medrol A, Medroxyprogesterone Acetate Greenstone) is a glucocorticoid, anti-inflammatory agent. It functions via Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist mechanism of action It is formulated as tablets for oral administration, lyophilized powder for solution, suspension and solution for intravenous, intramuscular, intraarticular, intralesional, intrasynovial route of administration. It is also formulated as enema for rectal administration and as ointment for topical administration. It is indicated in the treatment of encephalitis, optic neuritis, lupus erythematosus, allergic bronchitis, acquired (autoimmune) hemolytic anemia, pulmonary fibrosis, meningitis, hypoglycemia, rheumatoid arthritis, juvenile rheumatoid arthritis, polymyalgia rheumatica, uveitis, chorioretinitis, blepharitis, conjunctivitis, keratitis, scleritis,eczema,asthma,atopic dermatitis. Methylprednisolone was first approved in 1957 and is marketed globally including the US, the UK, France, Germany, China, and Japan by Pfizer Inc.